Skip to main content
Smart Investors Daily
CD

NASDAQ · CDIO

Cardio Diagnostics Holdings, Inc.

Healthcare · Biotechnology

$1.60

Down-$0.07 (-4.19%)

Updated Nov 4, 2026, 7:25 AM

SID Score

3.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
7.1M
P/E ratio
-1.08
Dividend yield
0.00%
52-week range
$0.97 – $7.91
Volume
7.84K
Avg. volume
35.8K

Price performance · CDIO

CDIO price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

CDIO closed at $1.60 after 21 trading sessions, down 20.00% for the selected period.

Last close
$1.60
Period change
-20.00%
Period low
$1.60
Period high
$2.00
Daily close
View OHLC price history
CDIO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$1.60$1.67$1.60$1.607.84K
Nov 2, 2026$1.74$1.74$1.63$1.673.66K
Oct 30, 2026$1.72$1.75$1.67$1.6712.04K
Oct 29, 2026$1.7281$1.78$1.70$1.755.71K
Oct 28, 2026$1.69$1.75$1.69$1.709.16K
Oct 27, 2026$1.72$1.73$1.68$1.709.06K
Oct 26, 2026$1.77$1.77$1.69$1.725.9K
Oct 23, 2026$1.795$1.795$1.69$1.6912.03K
Oct 22, 2026$1.80$1.80$1.69$1.70543.98K
Oct 21, 2026$1.805$1.84$1.71$1.7729.26K
Oct 20, 2026$1.64$1.7799$1.64$1.7253.14K
Oct 19, 2026$1.70$1.7271$1.55$1.6412.51K
Oct 16, 2026$1.78$1.8399$1.6874$1.696.81K
Oct 15, 2026$1.67$1.84$1.67$1.7627.33K
Oct 14, 2026$1.77$1.7792$1.67$1.6731.91K
Oct 13, 2026$1.86$1.86$1.75$1.7522.03K
Oct 12, 2026$1.90$1.91$1.655$1.7861.62K
Oct 9, 2026$1.90$1.95$1.87$1.8716.46K
Oct 8, 2026$1.99$1.99$1.85$1.8657.87K
Oct 7, 2026$1.995$2.03$1.95$1.9630.3K
Oct 6, 2026$2.02$2.07$1.98$2.0022.07K

Latest CDIO news

The latest Smart Investors Daily articles mentioning CDIO.

CDIO research

Overview

Company profile and research snapshot.

Company profile

Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$61.20
Implied upside
—
Analysts
7
CDIO recent ratings
DateFirmRatingTarget
Aug 27, 2024BenchmarkSpeculative Buy—
Jun 6, 2024BenchmarkSpeculative Buy—
Apr 19, 2024BenchmarkSpeculative Buy—
Jun 15, 2023BenchmarkSpeculative Buy—
May 22, 2023Northland Capital MarketsOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

ChartMill · Mar 2, 2026

Monday's session: top gainers and losers

Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.